Condition: Crohn Disease · Sponsor: Alimentiv Inc.
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.
This description comes directly from the study's public registry record.
Jennifer Earle · jennifer.earle@alimentiv.com
Anna Cheng · 416-705-3688 · anna.cheng@alimentiv.com
Always discuss trial participation with your own doctor first.
| Digestive & Liver Center of Florida | Orlando, Florida, United States | Recruiting |
| Velocity Clinical- Salt Lake City | Salt Lake City, Utah, United States | Active Not Recruiting |
| GI Institute Research Foundation | Vancouver, British Columbia, Canada | Recruiting |
| London Digestive Disease Institute | London, Ontario, Canada | Active Not Recruiting |
| The Office of Dr. Jason Reinglas | Scarborough Village, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06997965